Bridgewater Associates LP Decreases Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bridgewater Associates LP lessened its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 59.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,393 shares of the company’s stock after selling 13,829 shares during the period. Bridgewater Associates LP’s holdings in Teva Pharmaceutical Industries were worth $207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Oarsman Capital Inc. acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $29,000. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at about $66,000. IFP Advisors Inc grew its stake in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in shares of Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after acquiring an additional 949 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of research analyst reports. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Monday, April 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $13.61 on Monday. The stock has a market capitalization of $15.43 billion, a PE ratio of -9.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock’s 50-day moving average price is $15.45 and its 200-day moving average price is $17.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.